Cover Image
市場調查報告書

難辨梭狀芽孢桿菌傳染病 (困難梭狀芽孢桿菌相關疾病) :開發中產品分析

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255954
出版日期 內容資訊 英文 218 Pages
訂單完成後即時交付
價格
Back to Top
難辨梭狀芽孢桿菌傳染病 (困難梭狀芽孢桿菌相關疾病) :開發中產品分析 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 218 Pages
簡介

困難梭狀芽孢桿菌傳染病是消化道感染克陽性孢子形成菌系的微生物疾病。入院患者及照護(居家/設施雙方)者等常常會感染這個微生物的毒素,而引起消化器官的疾病。這個疾病的症狀包含有下痢、大腸炎、中毒性巨大結腸、敗血症等,這些一律概括稱之為「困難梭狀芽孢桿菌相關疾病」(CDAD)。

本報告提供全球各國治療難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病) 所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病) 概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):企業開發中的治療藥

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):大學/機關研究中的治療藥

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):企業開發中的產品

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):大學/機關研究中的產品

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病) 的治療藥開發企業

  • Absynth Biologics Limited
  • Actelion Ltd
  • Adenium Biotech ApS
  • AIMM Therapeutics B.V.
  • AmpliPhi Biosciences Corporation
  • Angothera GmbH
  • Appili Therapeutics
  • Assembly Biosciences, Inc.
  • AvidBiotics Corp.
  • C3 Jian, Inc
  • Da Volterra
  • 第一三共
  • e-Therapeutics Plc
  • Evec, Inc.
  • GangaGen Inc.
  • ImmunoBiology Limited
  • Immuron Limited
  • Inovio Pharmaceuticals, Inc.
  • Integrated BioTherapeutics, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MGB Biopharma Limited
  • Microbiotix, Inc.
  • Micropharm Limited
  • Morphochem AG
  • Nanotherapeutics, Inc.
  • Novabiotics Limited
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • 大塚集團
  • Pfizer Inc.
  • Procarta Biosystems Limited
  • Prokarium Limited
  • Rebiotix Inc.
  • Sanofi Pasteur SA
  • Seres Therapeutics, Inc.
  • Shire Plc
  • Sorrento Therapeutics, Inc.
  • Stellar Biotechnologies, Inc.
  • Summit Therapeutics Plc
  • Synthetic Biologics, Inc.
  • Valevia UK Limited
  • Valneva SE
  • VaxInnate Corporation

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):最近的開發平台趨勢

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):暫停中的計劃

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):開發中止的產品

難辨梭狀芽孢桿菌傳染病 (難辨梭狀芽孢桿菌相關疾病):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8583IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2016, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 11, 7, 32, 13 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 7 molecules, respectively for Clostridium difficile Infections.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview
  • Therapeutics Development
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Development by Companies
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Products Glance
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Development by Companies
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Investigation by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
  • Drug Profiles
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016
  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Angothera GmbH, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Antibiotx ApS, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corporation, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by e-Therapeutics Plc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Morphochem AG, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Procarta Biosystems Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Limited, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Venenum Biodesign, L.L.C, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..1), H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects (Contd..2), H2 2016
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016
  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top